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A MONG the commonly used antihypertensive drugs, only one, l-Hydra- zinophthalazine (Hydralazine), has been reported by various sources to 
produce an active dilatation of the renal vessels, when given parenterally to 
human subjects. l-3 No studies on the effects of administration of single oral doses, 
acceptable to the patient, have been reported, and with the exception of the 
report of Dustan and associates,’ and Moyer4 no information is available con- 
cerning the effects on the kidneys of long-term therapy with this drug. Since it 
was hoped that continued renal vasodilatation might reverse the pathologic 
vasoconstriction of the kidneys in hypertensive disease, it was of particular 
interest to observe the effect of acute and chronic oral administration of Hydrala- 
zine on the resting renal circulation and the basal blood pressure. Such observa- 
tions form the subject of this paper. 
METHODS 
1-Hydrazinophthalazine was administered in maximum tolerated oral doses, 
to seven patients with moderate “essential” hypertension but without azotemia, 
two of whom (V.G. and W.M.) had undergone a supradiaphragmatic splanch- 
nicectomy, eighth vertebral ganglion to twelfth vertebral ganglion, 15 to 17 
months previously. Before and at the end of an 11 to 15weeks period of such 
treatment, the renal blood flow response to a single oral dose of the drug was 
observed. Renal function was tested by the clearance of para-aminohippurate 
and inulin, according to conventional techniques. Patients were studied in the 
fasting state and the blood pressures and renal functions were determined during 
two 20-minute control periods after which the drug was given orally at the begin- 
ning of the third period. The blood and catheterized urine specimens were then 
collected over six additional intervals of 20 minutes each. The blood pressure 
for each period was recorded every 3 to 5 minutes throughout the entire pro- 
cedure, and the mean value for each period was calculated by dividing the average 
of all systolic and diastolic readings by two. The fluid intake was constant 
during the test, as the patients each received intravenously 750 C.C. of fluid 
containing para-aminohippurate and inulin, and routinely were given 120 C.C. 
of water or fruit juice orally at 45minute intervals. 
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During clinic visits when renal blood flow determinations were not performed, 
the resting mean blood pressure was calculated by averaging the first two OI 
three recumbent readings taken within 15 to 30 minutes after admission to the 
clinic. The blood pressure after the test dose was determined by taking the lowest 
mean recumbent reading during the day in the clinic, the patient remaining 
ambulatory in the interval between readings. The lowest blood pressure usually- 
occurred about equally after either the first dose at 9 A.M. or the second dose at 
12 noon. This system recorded the maximum possible reduction which could 
be ascribed to the drug. 
In addition to this study, the effects of Apresoline on the foot blood flow 
were studied in selected patients by means of the venous occlusion plethysmo- 
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Fig. l.-Effect of oral Apresoline on blood pressure and renal function. 
RESULTS 
1. E’ect on Renal Plasrncz &W.--The typical effect of a single oral dose of 
Hydralazine was to produce a significant increase in renal plasma flow without a 
significant change in glomerular filtration rate (Fig. 1). The renal vasodilator 
response was evident approximately 45 minutes after drug administration, was 
at its maximum in 2 to 2% hours, and returned to normal levels in 3% to 4 hours. 
A moderate reduction in systolic and diastolic blood pressures was also noted. 
Our data in all seven cases, studied before and at the end of the period of 
chronic treatment with the drug, is presented in Fig. 2. The mean renal plasma 
flow of our patients increased from 38.5 f 42.9 c.c./min.* to 523 =t 46.8 c.c./min.* 
following the initial administration of the drug. This difference was highly 
significant (p = 0.011). 
*.Mean and standard error of the mean 
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At the end of the 11 to 15 weeks of treatment the same dose increased the 
renal plasma flow from 419 f 43.9 c.c./min. to 422 f 66 c.c./min., which is en- 
tirely insignificant. Resting renal plasma flow was found to be significantly 
higher in three of the seven patients (E.V., S.C., E.Z.) at the conclusion of the 
treatment period. However, the mean change of all cases,* from 385 to 419 
c.c./min., was insignificant (p = 0.35). Crude renal resistances were found to 
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Fig. P.-Effect of oral Apresoline on renal plasma flow in hypertension. The shaded areas represent 
the meau resting renal plasma flow (average of two 20-minute periods before and one 20-minute period 
after oral administration of the effective dose of Apresoline. as indicated in Fig. 3). The open bars 
indicate the mean change for the fifth to the eighth 20-minute period (third to sixth after oral Apresoline). 
Renal resistances are calculated by the formula (mean blood pressure divided by renal plasma flow 
X Uhematocrit). It will be seen that substantial increases in renal plasma flow (average = +41 per 
cent) and decreases in renal resistance produced initially are less conspicuous at the conclusion of the 
treatment. The resting flows, however, increased slightly in three cases (EV. SC, and EZ) 
In contrast, however, there was an inconstant lowering of resistance of 6 per cent 
when the same oral dose was given after prolonged treatment. The drug altered 
the filtration fraction by a mean of - 2 1.6 per cent before and - 5 per cent after the 
treatment interval. The changes were due in large part to the alteration in renal 
plasma flow. The resting filtration rate and filtration fraction were not sig- 
nificantly affected by the prolonged treatment. 
2. Efect on Blood Pressure.-The blood pressure changes are individually 
plotted in Fig. 3 with the magnitude of the solid bars indicating the mean blood 
pressure reduction to equal doses of the drug given during the two renal blood 
*Mean and standard error of the mean. 
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flow determinations. Open bars represent the acute blood pressure changes to 
varying doses given during interim visits to the clinic in the treatment period. 
The size of these doses is recorded on the base line. They were often reduced at 
these visits because patients complained of side effects from larger amounts. 
The height of the shaded areas on the base line indicates the daily drug intake 
between clinic visits. The numerals above the bars indicate the mean blood 
pressures before each test dose was administered. It can be readily seen that no 
change in the basal blood pressure occurred as a result of prolonged treatment. 
Fig. 3.-Response of recumbent blood pressure to oral Apresoline therapy, Shows changes in 
mean blood pressure after acute and chronic administration of Apresoline to seven hypertensive patients. 
Method of calculation of the resting blood pressure and the change in blood pressure after the test doses 
is described in the section under “Methods” and the interpretation of the figure is as described in the 
text in the section under “Results.” 
Further inspection of Fig. 3 shows that the initial test do;e during the renal 
function test reduced the blood pressure significantly in six of the seven patients, 
the mean change being a -22 per cent. In contrast, the mean decrease in blood 
pressure during the final renal blood flow determination with the same oral dose 
was less prominent, representing a -8 per cent change and only two patients 
(W.M. and V.G.) showed a significant (i.e., greater than 10 per cent) response. 
This tolerance also extended to side effects, such as headache, dizziness, palpita- 
tion, nervousness and insomnia, which were much decreased on the second 
VANDlSRKOLK ET aI>. : APRESOLINE IN HYPERTENSION 99 
administration at the end of the treatment period. Because of the development 
of tolerance, attempts were made to elevate the dosage taken at home, but 
headaches and palpitation prevented us from making substantial increases. 
3. Effect on Foot Blood Flow.-Foot blood flow studies were done on seven 
patients, three of whom were also followed for their renal response to Hydralazine. 
In all cases a definite increase in flow was observed, occurring about 45 to 60 
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Fig. 4.-The effect of oral Apresoline on the foot blood flow as measured in the venous occlusion 
plethysmograph together with the changes in blood pressure and pulse rate. The definite vasodilator 
response to oral administration of the drug together with the widening of pulse pressure and increase of 
pulse rate suggests that a generalized vasodilatation is produced. 
The heart rate increased considerably and there was a decrease in blood pressure, 
especially diastolic. The mean flow in all our patients increased from 2.72 c.c.jlOO 
C.C. of foot volume per minute to 4.4 c.c./lOO C.C. of foot volume per minute. 
This represented a 43 per cent drop in regional resistance in this vascular bed, 
i.e., almost identical to that found in the renal area, in spite of the fact that the 
two areas are under quite unequal sympathetic tone. 
DISCUSSION 
The observations described above agree with those of Moyer” that Hydrala- 
zine is a potent renal vasodilator, but that tolerance to its renal effects is soon 
established. Dustan and associates’ also noted a failure of renal vasodilatation 
to occur after prolonged oral treatment with the drug, but stated that in certain 
cases an increase in the resting renal blood flow was observed after chronic 
treatment. We also observed slight increases in resting renal plasma flow in 
three of our patients after prolonged treatment. 
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Observations of tolerance to the depressor effects of acute administration of 
Hydralazine after chronic treatment have also been reported by Moyer.4 The 
report of Taylor and associates” does not include repeated careful studies of the 
acute response to oral administration of the drug before and after prolonged 
treatment, but it is reported that the blood pressure fell after treatment and rose 
when placebos were administered. Since the drug was given four times daily, 
it is probable that the blood pressure they recorded, particularly in the clinic, 
followed at least one dose of the drug and therefore does not represent changes in 
the “basal” level of the blood pressure. It should be emphasized that Hydrala- 
zine has a relatively transient effect and that the time since last administration 
of the drug is important in evaluating the blood pressure response. For the same 
reason it is not likely that drug administration during the day will affect blood 
pressure during the night unless the “basal” blood pressure level of the patient 
is reduced. This we have shown does not occur with the relatively small doses 
tolerated by our patients. 
That the drug is an active generalized dilator at least in hypertensive indi- 
viduals is demonstrated by our observation that peripheral blood flow in the foot 
is regularly increased, which parallels the observations of Wilkinson and asso- 
ciates3 and Schmid,’ who noted increased digital temperatures following paren- 
teral administration. Increases in splanchnic blood flow reported by Frei.9 also 
favor the concept that this drug is a generalized vasodilator. 
The mode of action is not clearly defined, but the following bits of evidence 
suggest that a peripheral or central sympathetic inhibition is not involved: (a) 
vasodilatation in the kidney is not blocked by pretreatment with hexamethonium4 
and (b) sympathetic inhibition with tetraethylammonium results in no increases 
in renal blood flow and greater increases in foot blood flow than here observed.gJO 
That the drug may have a direct action on the blood vessels themselves is sug- 
gested by (a) the widespread character of the vasodilatation, (b) the effect of 
intra-arterial administration in increasing local blood flow in animals” and local 
skin temperatures in man,3 and (c) absence of the hypotensive property of the 
drug in the spinal animals with a mean blood pressure of 60 and its reappearance 
if the blood pressure is raised with ephedrine.” It may be concluded that Hydra- 
lazine 6Apresoline) is an effective generalized vasodilator in hypertension but that 
tolerance to its effects is soon established and that the renal hyperemia initially 
produced by the drug does not lead to reduction of the basal blood pressure in 
established hypertension. 
CONCLUSIONS 
1. Well-tolerated oral doses of Hydralazine produce a definite and pro- 
longed renal vasodilatation associated with a moderate decrease in blood pressure 
and increase in heart rate. However, prolonged treatment diminishes these 
responses. 
2. In three of seven patients examined after two months or more of chronic 
treatment, there was a slight but definite increase in resting renal plasma flow, 
but no change in the basal blood pressure was noted in any of the patients studied. 
3. The extremital circulation shares in the vasodilator response to the drug, 
based on observations of foot blood flow in hypertensive patients. 
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